According to a new report from Intel Market Research, the Europe Empagliflozin Drug market was valued at USD 4,450 million in 2024 and is projected to grow from USD 5,125 million in 2025 to USD 12,585 million by 2032, growing at a robust CAGR of 17.0% during the forecast period (2025–2032). This growth is propelled by the rising diabetes prevalence with over 61 million adults affected in...